Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis and axial SpA.

Type of Molecule

Small Molecule



Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Atopic Dermatitis n/a
Phase 3
Crohn's Disease (CD) n/a
Phase 3
Psoriatic Arthritis n/a
Phase 3
Rheumatoid Arthritis (RA) EU, US
Ulcerative Colitis n/a
Phase 3
Axial SpA n/a
Phase 2